Table I.
Association between mRNA ERα and ERβ levels and standard clinicopathological factors and molecular settings.
| ERα | ERβ | ||||||
|---|---|---|---|---|---|---|---|
| Characteristics | Total population | Negative (%) | Positive (%) | P-value | Negative (%) | Positive (%) | P-value |
| Total | 32 (100%) | 10 (31.28) | 22 (68.75) | 11 (34.37) | 21 (65.62) | >0.05 | |
| Age | |||||||
| ≤50 years | 12 (37.5) | 4 (40) | 8 (36.36) | 5 (45.45) | 7 (33.33) | ||
| >50 years | 20 (62.5) | 6 (60) | 14 (63.63) | 0.13 | 6 (54.54) | 14 (66.66) | 0.06 |
| Grade | |||||||
| SBRI | 7 (21.87) | 4 (40) | 3 (13.63) | 4 (36.36) | 3 (14.28) | ||
| SBRII | 17 (53.12) | 3 (30) | 14 (63.63) | 5 (45.45) | 12 (57.1) | ||
| SBRIII | 8 (25) | 3 (30) | 5 (22.72) | 0.01 | 2 (18.18) | 6 (28.57) | 0.01 |
| Lymph node status | |||||||
| Positive | 17 (53.12) | 6 (60) | 11 (50) | 4 (36.36) | 13 (61.90) | ||
| Negative | 15 (46.87) | 4 (40) | 11 (50) | >0.05 | 7 (63.63) | 8 (38.09) | 0.20 |
| Tumor size | |||||||
| ≤30 mm | 22 (68.75) | 6 (60) | 16 (72.72) | 8 (72.72) | 14 (66.66) | ||
| >30 mm | 10 (31.25) | 4 (40) | 6 (27.27) | 0.006 | 3 (27.27) | 7 (33.33) | 0.06 |
| HER2 status | |||||||
| Positive | 8 (25) | 3 (30) | 5 (22.72) | 6 (72.72) | 2 (57.14) | ||
| Negative | 24 (75) | 7 (70) | 17 (77.27) | 0.0009 | 5 (27.27) | 19 (42.85) | 7.905−7 |
| Ki-67 | |||||||
| ≤5% | 9 (28.12) | 3 (44) | 6 (27.27) | 3 (27.27) | 6 (28.57) | ||
| >5% | 23 (71.87) | 7 (56) | 16 (72.72) | 0.0066 | 8 (72.72) | 15 (71.42) | 0.01 |
P-values calculated using the χ2 test in R. SBR, Scarff-Bloom-Richardson; HER2, human epidermal growth factor receptor 2; ER, estrogen receptor.